Aims: To establish the safety and efficacy of regional citrate anticoagulation (RCA) for pediatric liver failure (LF) patients receiving extracorporeal liver support (ELS) with albumin-assisted dialysis. Methods: Retrospective review of pediatric LF patients receiving ELS from April 2014 to December 2016 at a tertiary children’s hospital pediatric intensive care unit. Demographic and ELS data collected by chart review. Citrate accumulation (CA) was defined as total calcium (mmol/L): ionized calcium (mmol/L) > 2.5 (tCa:iCa). Efficacy was assessed by treatment duration. Safety was assessed by adverse events: bleeding, hemodynamic instability, arrhythmias, unplanned treatment discontinuation. Results: Fifteen patients (median age 3 [interquartile range (IQR) 0.7–8.0]) received 108 ELS treatments (median 5 [IQR 4–7.5]). Sixty-eight episodes of CA were identified. Of those, 6 coincided with intervention and 1 coincided with ELS discontinuation. There were no deaths attributed to ELS or RCA. Conclusion: RCA provides safe and effective anticoagulation for pediatric LF patients requiring ELS.

Keywords:
Extracorporeal liver support, Citrate anticoagulation, Pediatric
1.
Squires RH Jr: Acute liver failure in children. Semin Liver Dis 2008; 28: 153–166.
2.
Lutfi R, Abulebda K, Nitu ME, Molleston JP, Bozic MA, Subbarao G: Intensive care management of pediatric acute liver failure. J -Pediatr Gastroenterol Nutr 2017; 64: 660–670.
3.
Neri M, Villa G, Garzotto F, Bagshaw S, Bellomo R, Cerda J, Ferrari F, Guggia S, Joannidis M, Kellum J, Kim JC, Mehta RL, Ricci Z, Trevisani A, Marafon S, Clark WR, Vincent JL, Ronco C: Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care 2016; 20: 318.
4.
Villa G, Neri M, Bellomo R, Cerda J, De Gaudio AR, De Rosa S, Garzotto F, Honore PM, Kellum J, Lorenzin A, Payen D, Ricci Z, Samoni S, Vincent JL, Wendon J, Zaccaria M, Ronco C: Nomenclature for renal replacement therapy and blood purification techniques in critically ill patients: practical applications. Crit Care 2016; 20: 283.
5.
Ronco C, Ricci Z, De Backer D, Kellum JA, Taccone FS, Joannidis M, Pickkers P, Cantaluppi V, Turani F, Saudan P, Bellomo R, Joannes-Boyau O, Antonelli M, Payen D, Prowle JR, Vincent JL: Renal replacement therapy in acute kidney injury: controversy and consensus. Crit Care 2015; 19: 146.
6.
Squires R Jr, Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, Dhawan A, Rosenthal P, Rodriguez-Baez N, Murray KF, Horslen S, Martin MG, Lopez MJ, Soriano H, McGuire BM, Jonas MM, Yazigi N, Shepherd RW, Schwarz K, Lobritto S, Thomas DW, Lavine JE, Karpen S, Ng V, Kelly D, Simonds N, Hynan LS: Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148: 652–658.
7.
Stange J: Extracorporeal liver support. Organogenesis 2014; 7: 64–73.
8.
Link A, Klingele M, Speer T, Rbah R, Poss J, Lerner-Graber A, Fliser D, Bohm M: Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care 2012; 16:R97.
9.
Fernandez SN, Santiago MJ, Lopez-Herce J, Garcia M, Del Castillo J, Alcaraz AJ, Bellon JM: Citrate anticoagulation for CRRT in children: comparison with heparin. Biomed Res Int 2014; 2014: 786301.
10.
Oudemans-van Straaten HM, Kellum JA, Bellomo R: Clinical review: anticoagulation for continuous renal replacement therapy – heparin or citrate? Critical Care 2011; 15: 202.
11.
Mariano F, Bergamo D, Gangemi EN, Hollo’ Z, Stella M, Triolo G: Citrate anticoagulation for continuous renal replacement therapy in critically ill patients: success and limits. Int J Nephrol 2011; 2011: 748320.
12.
Davenport A, Tolwani A: Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus 2009; 2: 439–447.
13.
Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260–265.
14.
Rico MP, Fernandez Sarmiento J, Rojas Velasquez AM, Gonzalez Chaparro LS, Gastelbondo Amaya R, Mulett Hoyos H, Tibaduiza D, Quintero Gomez AM: Regional citrate anticoagulation for continuous renal replacement therapy in children. Pediatr Nephrol 2017; 32: 703–711.
15.
Patel S, Wendon J: Regional citrate anticoagulation in patients with liver failure–time for a rethink? Crit Care 2012; 16: 153.
16.
Denlinger JK, Nahrwold ML, Gibbs P, Lecky JH: Hypocalcaemia during rapid blood transfusion in anaesthetized man. Br J Anaesth 1976; 48: 995–1000.
17.
Kramer L, Bauer E, Joukhadar C, Strobl W, Gendo A, Madl C, Gangl A: Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31: 2450–2455.
18.
Meier-Kriesche H-UG, Jeremy; Finkel, Kevin; DuBose, Thomas: Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 2001; 29: 5.
19.
Rodriguez K, Srivaths PR, Tal L, Watson MN, Riley AA, Himes RW, Desai MS, Braun MC, Akcan Arikan A: Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure. PLoS One 2017; 12:e0182134.
20.
Ricci Z, Ronco C, Bachetoni A, D'Amico G, Rossi S, Alessandri E, Rocco M, Pietropaoli P: Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care 2006; 10:R67.
21.
Meijers B, Laleman W, Vermeersch P, Nevens F, Wilmer A, Evenepoel P: A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System. Crit Care 2012; 16:R20.
22.
Faybik P, Hetz H, Mitterer G, Krenn CG, Schiefer J, Funk GC, Bacher A: Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system. Crit Care Med 2011; 39: 273–279.
23.
Doria C, Mandala L, Smith JD, Caruana G, Scott VL, Gruttadauria S, Magnone M, Marino IR: Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system. Clin Transplant 2004; 18: 365–371.
24.
Tan HK, Yang WS, Chow P, Lui HF, Choong HL, Wong KS: Anticoagulation minimization is safe and effective in albumin liver dialysis using the molecular adsorbent recirculating system. Artif Organs 2007; 31: 193–199.
25.
Tan HK, Yang WS, Choong HL, Wong KS: Albumin dialysis without anticoagulation in high-risk patients: an observational study. Artif Organs 2012; 36:E83–E88.
26.
Yang WS, Tan HK, Lui HF, Chow PK, Choong HL, Wong KS: Albumin dialysis in critically ill patients: use versus omission of intradialytic heparin. Artif Organs 2008; 32: 411–416.
27.
Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, Larsen FS, Gornbein J, Stange J, Blei AT: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853–1862.
28.
Lexmond WS, Van Dael CM, Scheenstra R, Goorhuis JF, Sieders E, Verkade HJ, Van Rheenen PF, Komhoff M: Experience with molecular adsorbent recirculating system treatment in 20 children listed for high-urgency liver transplantation. Liver Transpl 2015; 21: 369–380.
29.
Akcan Arikan A, Srivaths P, Himes RW, Tufan Pekkucuksen N, Lam F, Nguyen T, Miloh T, Braun M, Goss J, Desai MS: Hybrid extracorporeal therapies as a bridge to pediatric liver transplantation. Pediatr Crit Care Med 2018; 19:e342–e349.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.